The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 14.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.
Nutex Health Inc.
NUTX · Nasdaq · USD · Market cap $1.3B · 1,005 employees
Nutex Health Inc.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price173.67 USD at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkdown, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $180.00 to $282.31, base estimate $245.48 (screen dated 2026-11-13).
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
Nutex Health Inc. holds its Markdown at $173.67. Consolidating, no directional conviction, held for 1 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 1 days |
| Price at the screen | $173.67 |
| Valuation | 7.67 trailing · 9.52 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 2.01 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 38.26% | Below 33% | Interest-bearing debt is 38.3% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 55.63% | Below 49% | Money owed to the company is 55.6% of assets, above the 49% limit. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Nutex Health's business is in a permissible area, but its interest-bearing debt is about 38% of the company, just over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when NUTX's ethical verdict changes
Today NUTX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 29% discount to our $245.48 fair value.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 29.3% discount to the base estimate.
Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +77% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $245.48, with a range of $180.00 to $282.31, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsMicro hospitals with flat growth earn a pass
Every time someone turns up at a micro hospital needing quick care, the visit should add up. Nutex runs a network of these facilities across three segments yet revenue is rising just 2 percent a year. That single figure overrides the 54 percent ROE and 11 percent margins that look attractive on paper.
The forward multiple of 8 times earnings appears cheap next to our fair value estimate, but the market is right to withhold enthusiasm when top-line growth has stalled. Five analysts see a median target well below where the shares now trade, and an unknown moat leaves little visibility on whether those returns can last.
Risk sits in the lack of scale and the thin revenue line that makes any hiccup in patient volumes or reimbursement rates hit hard. Ethical screen cleared, yet the numbers still give no reason to step in. Analysis, not advice.
| Forward P/E | 9.5xvery cheap relative to earnings |
| Trailing P/E | 7.7xvery cheap relative to earnings |
| EPS, trailing | 25.24 |
| EPS, forward | 20.33 |
| Revenue growth | -13.6%revenue is shrinking |
| Profit margin | 21.2%healthy profit margins |
| Return on equity | 64.6%an exceptional return on shareholder capital |
| FCF yield | 9.86% |
| Debt to equity | 0.68moderate, manageable leverage |
| Current ratio | 5.00comfortably covers its short-term bills |
| Beta | 2.01much more volatile than the market |
| Short interest, float | 0.29% |
| 52-week range | 83.99 - 226.16 |
| Market cap | $1.3B |
| Employees | 1,005 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeNUTX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 51%. The street (3 analysts) rates it none, with a mean price target of $236.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Nutex Health Inc (NUTX) (Q3 2026) Earnings Call Highlights: Net Income Jumps 159% Despite ... Yahoo Finance · 3d ago
- NUTX Q3 Earnings Call Highlights Reimbursement and Hospital Growth Yahoo Finance · 7d ago
- Nutex Health Named a 2026 Houston Top Workplace by Houston Chronicle Yahoo Finance · 7d ago
- Nutex Health (NUTX) Q3 2026 Earnings Call Transcript Yahoo Finance · 9d ago
- Nutex Health Q3 Earnings Call Highlights Yahoo Finance · 10d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $132.88 | +1.3% | · | $1,013 | +1.3% |
| 2 months | $101.05 | +33.3% | · | $1,333 | +33.3% |
| 3 months | $87.01 | +54.8% | · | $1,548 | +54.8% |
| 6 months | $190.49 | -29.3% | · | $707 | -29.3% |
| 1 year | $117.17 | +14.9% | · | $1,149 | +14.9% |
| 2 years | $6.08 | +2,114.8% | · | $22,148 | +2,114.8% |
| 3 years | $66.75 | +101.7% | · | $2,017 | +101.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NUTX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.